In a new job – March 6, 2026
Gavin Wood has been appointed new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026.
Business article – March 6, 2026
The changes are a result of the divestment of Zubsolv in the US market and focus on advancing development programs and the AmorphOX technology.
Pharma Business – March 4, 2026
The company is opening of a new 8,000-square-meter center supporting its immunodiagnostics business in Uppsala.
Upcoming events – March 4, 2026
Vitalis, a four-day event held at Svensk Mässan in Gothenburg on May 4-7, will deliver insight, strategy, and connections – both within and beyond the sessions – that drive the future of healthcare.
Financing – March 3, 2026
Through the directed issue, the company will receive approximately SEK 51.9 million.
Biotech article – March 3, 2026
Nasal drug delivery is a dynamic area in pharmaceutical innovation. What was once a route for decongestants and allergy sprays is now being explored for everything from emergency treatments to vaccines – and even shows potential for future central nervous system therapies.

Opinion & debate
Clinical Trials – February 10, 2026
The company has announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously.
Clinical Trials – February 2, 2026
SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.
Clinical Trials – January 27, 2026
The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).
Clinical Trials – January 27, 2026
The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.
Clinical Trials – January 12, 2026
Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.
Clinical Trials – January 9, 2026
Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.
PharmaRelations
This is a position that combines strategic oversight, business development, and team leadership. The successful candidate will play a pivotal role in shaping our services to our customers.
PharmaRelations
This is a leadership position that combines strategic oversight, business development, and team leadership. The successful candidate will play a pivotal role in shaping our qualtiy assurance services to our customers.
Conaxess Trade
A high‑impact role where you take ownership of QA across the Nordics and help shape the future of leading self‑care brands. Ready to make your mark?
Confidential
PharmaRelations, together with the Board of Directors, are seeking an experienced and visionary CEO to lead a rapidly growing Life Science company through its next phase of development and growth. The company is based in southern Sweden.
Stryker
Looking for a place that values your unique talents? Discover Stryker’s award-winning culture.
GEA Process Engineering
GEA – “Engineering for a better world”. GEA, one of the world’s largest systems suppliers for the Food, Beverage, and Pharmaceutical sectors.
In a new job – March 3, 2026
The Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons.
In a new job – February 5, 2026
Gauthy, who has played a central role in building Zelluna’s manufacturing and CMC capabilities since joining in 2022, assumes the role with immediate effect.
In a new job – January 29, 2026
After close to ten years as CEO, Annette Säfholm has decided to step down from her role. The Board of Directors has appointed Julie Waras Brogren as the new Chief Executive Officer.
Career choice – February 16, 2026
María Bueno Álvez is a final-year PhD student at SciLifeLab and the KTH Royal Institute of Technology. She works in the Human Protein Atlas under the supervision of Professor Mathias Uhlén.
Careers article – February 15, 2026
The method of storytelling has been an excellent way to spread information, knowledge and experiences for centuries.
Careers article – February 3, 2026
At Elekta’s Strategic Update for investors the company announced that, as a consequence of the company’s new operating model, it is reducing the number of employees by 450.
Profiles in Business – December 8, 2025
Successful businessman and former chairman of AstraZeneca, Leif Johansson, has accumulated vast experience and knowledge about international competition, leadership, business development, and entrepreneurship, not least when it comes to science-driven industries like the life science industry.
Nobel Prize 2025 – November 25, 2025
With a family legacy in medicine dating back to the Shogun era, the Japanese immunologist Dr. Shimon Sakaguchi has dedicated his career to the science. A 30-year-old pivotal discovery led him to this year’s Nobel Prize in Physiology or Medicine for research in peripheral immune tolerance.
Nobel Prize 2025 – November 25, 2025
Nobel Prize laureate Mary E. Brunkow’s career path has shifted between industry and academia but her end goal to generate clinical benefit and her passion for exploring new areas have never wavered.
Biotech article – March 3, 2026
Elicera Therapeutics provides an update on the development of its iTANK-armed CAR T-cell therapy candidate ELC-401 for the treatment of recurrent glioblastoma.
CDMO – March 1, 2026
When His Royal Highness Prince Daniel and visitors from the Royal Swedish Academy of Engineering Sciences visited NorthX Biologics up in Matfors in northern Sweden, the company chose a somewhat different approach.
Financing – February 24, 2026
The Board of Directors has resolved to carry out a new share issue of approximately SEK 200 million with preferential rights for the company’s existing shareholders based on the authorization granted by the Annual General Meeting on 22 May 2025.
MedTech Business – March 2, 2026
The company has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure.
MedTech Business – February 23, 2026
The US Food and Drug Administration (FDA) has informed the company that it can proceed with the proposed clinical investigation for FG001.
Digital health – February 16, 2026
It is the first AI operating system in Europe to achieve registration in EUDAMED as a medical device, according to the company.
Biotech Business – February 25, 2026
The company’s Biologics License Application (BLA) for imlifidase has been accepted by the U.S. Food and Drug Administration (FDA).
Biotech Business – February 24, 2026
The investment supports the continued development and scaling of the company’s antibody technology platforms, enabling expanded application areas and strengthened industry collaborations.
Biotech Business – February 23, 2026
Beactica Therapeutics, together with glioblastoma researchers at KU Leuven, has been awarded the grant to advance a precision immune therapy for glioblastoma.
Science News – March 3, 2026
Researchers at the University of Turku have discovered and characterised at the atomic level a mechanism that enables bacterial pathogens – including hospital bacteria Acinetobacter baumannii and Pseudomonas aeruginosa – to assemble antibiotic-resistant three-dimensional (3D) biofilms.
Science Award – February 12, 2026
This year’s Sjöberg Prize of one million US dollars is awarded to a British cancer researcher who has provided fundamental knowledge about evolution in tumours.
Science News – February 10, 2026
Data from Finnish and Swedish cohorts link specific RAS mutation subtypes to distinct treatment outcomes, strengthening the evidence base for biomarker‑guided therapy.
Upcoming events
This site uses cookies